Known targets — ChEMBL curated mechanism
MTORPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5
The experimentally established mechanism targets of Voxtalisib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA known ✓ | P42336 | 16/20 | 1.00 |
| ▸ | MTOR known ✓ | P42345 | 4/20 | 1.00 |
| ▸ | PIK3CD known ✓ | O00329 | 1/20 | 1.00 |
| ▸ | PIK3CB known ✓ | P42338 | 1/20 | 1.00 |
| ▸ | PIK3CG known ✓ | P48736 | 1/20 | 1.00 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
| ▸ | COMT | P21964 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1899832 | 0.88 | PIK3CA (0.78) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1901964 | 0.84 | PIK3CA (0.73) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL189553 | 0.84 | PIK3CA (0.73) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL188666 | 0.84 | PIK3CA (0.72) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1900964 | 0.82 | MTOR (0.69) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1898116 | 0.82 | PIK3CA (0.69) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL10263939 | 0.82 | PIK3CA (0.69) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL189211 | 0.80 | PIK3CA (0.67) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL4215756 | 0.80 | PIK3CA (0.67) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL1900230 | 0.80 | PIK3CA (0.66) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 249 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | SOVARGEN CO LTD (KR) | 2026-02-12 | — | — | US | claimed |
| US-12453733-B2 | Composition for prevention or treatment of intractable epilepsy comprising mTOR inhibitor | SOVARGEN CO., LTD. (KR) | 2025-10-28 | — | — | US | claimed |
| EP-4605376-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-08-27 | — | — | EP | claimed |
| CN-120202190-A | Isoquinoline derivatives as protein degrading agents, E7 degrading agents, antiviral agents, tumor therapeutic agents and immunosuppressants | RDP制药股份公司 | 2025-06-24 | — | — | CN | claimed |
| EP-4548977-A2 | NOVEL ISOQUINOLINES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | RDP Pharma AG (CH) | 2025-05-07 | — | — | EP | claimed |
| WO-2024083802-A1 | ISOQUINOLINE DERIVATIVES AS PROTEIN DEGRADERS, E7 DEGRADERS, ANTIVIRALS, TUMOR THERAPEUTICS AND IMMUNE SUPPRESSIVES | VALDOSPAN GMBH (AT) | 2024-04-25 | — | — | WO | claimed |
| EP-4322949-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | RDP Pharma AG (CH) | 2024-02-21 | — | — | EP | claimed |
| CN-117377474-A | Isoquinoline derivatives as antiviral and antitumor agents | RDP制药股份公司 | 2024-01-09 | — | — | CN | claimed |
| WO-2022219157-A1 | ISOQUINOLINE DERIVATIVES FOR USE AS ANTIVIRAL AND ANTITUMOUR AGENTS | VALDOSPAN GMBH (AT) | 2022-10-20 | — | — | WO | claimed |
| US-20220112625-A1 | Diagnosing and Treating Neurological and Autoimmune Diseases by Optimizing Metabolic Responses | POSTREL RICHARD (US) | 2022-04-14 | — | — | US | claimed |
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | EXELIXIS, INC (US) | 2013-07-04 | — | — | US | claimed |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2012-11-29 | — | — | US | claimed |
| EP-2056829-B9 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-09-26 | — | — | EP | claimed |
| EP-2056829-B1 | USING PI3K AND MEK MODULATORS IN TREATMENTS OF CANCER | EXELIXIS INC (US) | 2012-01-04 | — | — | EP | claimed |
| US-8044062-B2 | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha | EXELIXIS, INC. (US) | 2011-10-25 | — | — | US | claimed |
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | EXELIXIS, INC. (US) | 2011-09-29 | — | — | US | claimed |
| EP-2322523-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | claimed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | EXELIXIS, INC. (US) | 2010-03-25 | — | — | US | claimed |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | EXELIXIX, INC. (US) | 2009-10-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075947-A1 | Methods of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CA 1/4885MTOR 45/4885PIK3CD 2/4885 |
| US-20090270430-A1 | Pyridopyrimidinone Inhibitors of Pl3Kalpha | PLK3, PLK4, PLK2 | PIK3CA 67/4885MTOR 2128/4885PIK3CD 75/4885 |
| US-20120302545-A1 | Method of Using PI3K and MEK Modulators | PIK3CA, PIK3CD, PIK3R1 | PIK3CA 1/4885MTOR 42/4885PIK3CD 2/4885 |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | PIK3CA 85/4885MTOR 559/4885PIK3CD 260/4885 |
| US-20260041692-A1 | COMPOSITION FOR PREVENTION OR TREATMENT OF INTRACTABLE EPILEPSY COMPRISING mTOR INHIBITOR | MTOR, MAPKAP1, RPTOR | PIK3CA 347/4885MTOR 1/4885PIK3CD 100/4885 |
| US-20110237608-A1 | Pyridopyrimidinone Inhibitors of PI3Kalpha | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885MTOR 53/4885PIK3CD 2/4885 |
| US-20130172371-A1 | Methods of Treating Cancer Using Pyridopyrimidinone Inhibitors of PI3K and mTOR in Combination with Autophagy Inhibitors | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885MTOR 1/4885PIK3CD 3/4885 |
| US-12453733-B2 | Composition for prevention or treatment of intractable epilepsy comprising mTOR inhibitor | MTOR, MAPKAP1, RPTOR | PIK3CA 358/4885MTOR 1/4885PIK3CD 146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.